Introduction
At present, in reproductive medicine, endometrial loss or insufficient endometrial thickness has become one of the main problems that affect the successful implantation and normal growth of embryos. Therapeutic methods used to promote endometrial regeneration at home and abroad include exogenous estrogen, low-dose aspirin, sildenafil citrate, pentoxifylline, vitamin E, L-arginine, cytokines, electroacupuncture, and biofeedback therapy. Although these treatments claim to improve the implantation and pregnancy rates during the assisted reproductive technology cycle, from the perspective of evidence-based medicine, various methods for treating thin endometrium seem to be useless and inefficient, and patients with thin or even deficient endometrium are not likely to attempt pregnancy through assisted reproduction.1 Therefore, researchers have been exploring innovative interventions for the treatment of thin endometrium and endometrium loss.
New measures to treat thin endometrium and endometrium deletion are urgently needed in the clinical setting. According to the existing knowledge, oviduct mucosa and endometrium have many similarities in tissue structure and function. In terms of tissue structure, they share the homology of embryo origin. The cellular components of mucosa and intima are composed of epithelial and mesenchymal components, and the epithelial cells are mainly composed of ciliary and secretory cells, with similar cell morphology but different cell proportion. In terms of function, both of these two mucous membranes undergo morphological, physiological, and biochemical changes, along with changes in ovarian hormones, during the menstrual cycle. These changes have many similarities and are the necessary basis for the formation and growth of early embryos.2 For example, oviduct and uterine fluids contain growth factors, cytokines, proteins, metabolites, etc., which provide nutritional support and immune protection for the normal growth and development of early embryos.3,4 Oviduct mucosa and endometrium have the same implantation window.57 Studies have confirmed that the chromosome analysis of trophoblast cells of embryos from ectopic salpingocyesis is not significantly different from that of normal intrauterine pregnancy, so it is considered that salpingocyesis is the implantation of normal embryos in oviduct mucosa.8 Based on that, we hypothesized that placing oviduct mucosa into the uterine cavity to perform the endometrium function might be a way to treat thin endometrium and endometrium loss. Therefore, we co-cultured primary oviduct mucosa cells and endometrial cells to understand the growth of the two types of cells during co-culture and to simulate different levels of intimal loss, to observe the growth and status of oviduct mucosa cells cultured under the condition of endometrium deletion, and to lay a foundation for the possibility of replacing endometrium with oviduct mucosa in the treatment of intrauterine adhesions (IUA).
At the Affiliated Hospital of Guizhou Medical University from November 2019 to December 2020, oviduct mucosa and endometrium were collected from 22 gynecological patients who needed to have their endometrium, oviduct, and uterus removed due to infertility, myoma of the uterus, adenomyosis, CIN III, and other diseases. The average age of the patients was 39.4 years old, and most of these patients were in the middle of their menstrual cycle (late proliferation). The postoperative pathological examination proved that there were no malignant pathological changes in the oviduct and endometrium, and they had not taken steroid hormones three months before surgery.
The 22 participants were selected for this study for the following reasons: 1. All of these 22 patients need to have their fallopian tubes removed due to their condition, and specimens of fallopian tubes can be taken for this experiment; 2. These 22 patients need to have endometrial biopsy at the same time, and there is residual endometrial tissue available for this experiment; 3. Carry out the experiment in the article, 22 patients specimens are just enough to repeat this experiment 3 times; 4. These 22 patients are all non-malignant tumor diseases, and the pathological examinations of fallopian tube mucosa and endometrial are normal, which is suitable for this Research; 5. These patients are all at childbearing age, have regular menstrual cycles, and have no endocrine diseases.
All tissue samples were collected with informed consent signed by the patients. The Ethics Committee of the Affiliated Hospital of Guizhou Medical University approved this study.
After the uterus and oviduct were removed from the body, the endometrium was taken immediately, and oviduct mucosa was separated and collected in sterile specimen bottles containing normal saline. The samples were stored at 4C and sent to the laboratory within 1 h. The specimens were removed and placed in a Petri dish with a diameter of 3.5 cm. The surface red blood cells were washed with phosphate buffer solution (PBS) three times, and the tissues were cut into small pieces less than 1 mm. The tissue pieces were moved to a 15 mL centrifuge tube with a pipette, washed once with PBS solution, and centrifuged for 5 min at 1,200 r/min, and the supernatant was discarded. A 0.1 mg/mL of type I collagenase (C0103, Sigma) was added for digestion and placed in a 37C constant temperature water bath, during which the digestion was vibrated every 10 min. After 90 min of digestion, Dulbeccos Modified Eagle Media: Nutrient Mixture F-12 (DMEM/F12) was added to terminate digestion. The endometrium and oviduct mucosal suspensions were centrifuged at 1,200 r/min for 5 min to remove the supernatant and obtain the sediment. A 10% fetal bovine serum (super fetal bovine serum [South America], 04-001-1ACS, BI) was added to the two sediments respectively, blown and mixed well, and inoculated in a cell culture flask. The endometrium and oviduct mucosal cell culture bottles were incubated in a CO2 incubator at 37C for 24 h to observe cell attachment and growth. If the cells were attached and growing well, the solution was changed every 48 h, and the cell morphology was observed with an inverted microscope.
When the bottom of the culture bottle was about 80~90% full of cells, the original medium was discarded and washed twice with PBS, 0.25% pancreatic enzymes were added just above the bottom of the bottle, and the culture bottle was placed in an incubator with 5% CO2 at 37C for digestion for 12 min. After the cells were suspended, digestion was stopped with DMEM-F12, which was 45 times the volume of the pancreatic enzymes, and centrifuged at 1,200 r/min for 5 min. The supernatant was removed, and the cell sediment was retained. A 10% fetal bovine serum complete medium was added to the cell sediment, thoroughly beaten and mixed, and a 105 cell suspension was inoculated in the culture flask. A 10% fetal bovine serum complete medium was supplemented in the culture flask to 6 mL and placed in an incubator of 5% CO2 at 37C.
The second generations endometrial and oviduct mucosa cells, which were in a logarithmic growth phase and good growth state, were selected. The sterile slides were placed into a 12-well Petri dish, and the slides were taken out at a rate of 4104 cells per well when the cells had grown to cover about 8090% of the slides. The slides were then fixed with 4% formaldehyde for 15 min and 0.5% Triton X-100 membrane broken for 20 min, sealed with 10% normal goat serum PBS for 30 min, rabbit anti-cytokeratin (Cytokeratin 19 Antibody, 10712-1-AP, ProteinTech, 1:300), and PBS (blank control) and were incubated overnight in the dark at 4C. The first antibody was recovered, washed with PBS three times, and then incubated with goat anti-rabbit green fluorescent second antibody (488, SA00006-2, ProteinTech, 1:200) for 1 h. Then it was washed with PBS three times for 5 min each time, a small amount of DAPI staining was added for 5 min, dried, sealed with an anti-fluorescent quenching agent, and preserved under a fluorescence microscope. When the endometrial cells and oviduct mucosa cells were subcultured to the fifth generation, the cells with good growth status and logarithmic growth phase were identified with Vimentin antibody (10366-1-AP, ProteinTech, 1:300). The secondary antibody was marked by red fluorescence Alexa Fluor 594-conjugated Goat Anti-rabbit IgG (H+L) (SA00006-4, ProteinTech, 1:200). The steps were the same as above, photographed and saved by fluorescence microscope.
The groups were as follows:
A. oviduct mucosal cells (control group);
B. endometrial cells (upper chamber) + oviduct mucosal cells (lower chamber), cell ratio of the upper chamber:lower chamber was 1:1 (experimental group 1);
endometrial cells (upper chamber) + oviduct mucosal cells (lower chamber), cell ratio of the upper chamber:lower chamber was 0.5:1 (experimental group 2);
endometrial cells (upper chamber) + oviduct mucosal cells (lower chamber), cell ratio of the upper chamber:lower chamber was 0.1:1 (experimental group 3).
Cell co-culture and decidualization: the fifth-generation oviduct mucosa cells in the logarithmic growth phase and good growth state were selected, and 1.8105 cells/well were inserted into the six-well plate to grow simultaneously in the lower chamber. At the same time, the fifth generation of endometrial cells, which were in a logarithmic growth stage and good growth state, were collected and inserted into the upper chamber with 1.8 105, 9 104, and 1.8104 cells per well.
Endometrial cells and oviduct mucosal cells were co-cultured with 2% fetal bovine serum after the cells adhered to the wall. After 48 h of culture, change to the medium for inducing cell decidualization (ingredients of the medium for inducing cell decidualization: cell culture medium with 2% fetal bovine serum, 1 m progestational hormone [Progesterone, V900699, Sigma], 10 nM 17- estradiol [-Estradiol, E110145, Aladdin], 0.5 mM 8-Br-cAMP [8-Bromoadenosine 3,5-cyclic monophosphate, B5386, Sigma]) was continuously cultured for 96 h; cell growth and cell changes after decidualization were observed under an inverted microscope.
The third generation of oviduct mucosal cells, which were in the logarithmic growth phase and good growth state, were added to the lower compartment of a 24-well plate at a rate of 5103 cells per hole. At the same time, the third generation of endometrial cells in the logarithmic growth phase and good growth state were collected and placed into the upper chamber with 5 103, 2.5 103, 5 102/well plates. Endometrial cells were cultured with oviduct mucosa cells after the cells adhered to the wall. The same group was incubated for seven consecutive days. The tunnel chamber was removed daily, and the medium was sucked out of the 24-well plate, and 500 L fresh medium was added for each well, and 50 L CCK8 was added to each well and cultured at 37C for 2 h. Each well absorbed 100 L of the medium and was added to the 96-well plate. Each well had three replicas. The absorbance value of each well was measured by OD (optical density) at 450 nm by the enzyme calibration.
The cell slides were placed in the lower and upper compartments of the 12-well plate co-cultured in the compartment. The fifth generation of oviduct mucosal cells in the logarithmic growth phase and good growth state were taken and inserted into the lower compartment slides of the 12-well plate co-cultured at a rate of 4104 cells per hole. At the same time, endometrial cells of the fifth generation, which were in a logarithmic growth phase and good growth state, were collected and inserted into 12-well plates to grow the upper chamber. Endometrial cells were cultured with oviduct mucosal cells after the cells were attached to the slit. The grouping method was the same as above. After decidualization, the four groups of cell slides were soaked with PBS three times, 3 min each. The slide was fixed with 4% paraformaldehyde for 15 min, and the slide was soaked by PBS three times, 3 min each. The climbing film was dripping with Mayers hematoxylin (with a clean staining background, without differentiation), dyed for 10 min, and washed and soaked in tap water to return to blue. Next, the climbing film was dripping with 1% water-soluble eosin dye for 5 min, washed and soaked in tap water for 30 s, 95% alcohol I for 30 s, 95% alcohol II for 1 min, absolute ethyl alcohol I for 5 min, absolute ethyl alcohol II for 5 min, xylene I for 5 min, and xylene II for 5 min, and sealed with neutral balsam after air drying; this was then examined with a microscope.
Normally distributed variables were expressed as mean s.d. For repeated measurement data, repeated measurement ANOVA was used. P-values less than 0.05 were considered statistically significant. Analyses were carried out using the GraphPad (version 7.0; GraphPad Software, Inc.) and SPSS software (version 22.0; IBM Corp).
The primary cultured cells were observed under an inverted microscope. Endometrial cells were completely adherent within 24 h, and oviduct mucosa cells adherent after 48 h. Both cells were polygonal, tadpole, and spindle types in the primary culture and early passage. The nucleus was centered and round, and the cells gathered and grew like islands. Most of the cells began to change in morphology after passage to the third generation and gradually appeared as long fusiform. By the fifth generation, most cells grew into fusiform, similar to the fibrous cells (Figure 1).
Figure 1 The primary cultured cells were observed under an inverted microscope. Endometrial cells were completely adherent within 24 hours and oviduct mucosa cells adherent after 48 hours. Both cells were polygonal, tadpole and spindle type in primary culture and early passage. The nucleus was centered and round, and the cells gathered and grew like islands. Most of the cells began to change in morphology after passage to the third generation, and gradually appeared long fusiform. By the fifth generation, most of the cells grew into fusiform, similar to fibrous cells. (A) Primary endometrial cells; (B) primary oviduct mucosal cells; (C) the third generation of endometrial cells; (D) the third generation of oviduct mucosal cells; (E) the fifth generation of endometrial cells; (F) the fifth generation of oviduct mucosal cells.
Immunofluorescence identification of epithelial marker keratin antibody was performed on endometrial and oviduct mucosa cells passed to the second generation. The results showed that 8090% of the cytoplasm of endometrial and oviduct mucosa cells were stained with green fluorescence after passage to the second generation, showing positive cytokeratin antibodies. Microscopically, the cells were polygonal, spindle and spindle. Immunofluorescence identification of interstitial cell marker vimentin antibody was performed on endometrial and oviduct mucosa cells passed to the fifth generation. Eighty percent of the cytoplasm of endometrial and oviduct mucosa cells were stained with red fluorescence under a microscope. It showed a positive cell vimentin antibody, and the cells were fusiform and polygonal under the microscope. According to the results of cell identification, the majority of the two kinds of cells were still epithelial cells before the second passage, and the epithelial cells gradually transformed into mesenchymal cells when the passage continued. After the fifth passage, the cultured cells were mainly stromal (Figure 2).
Figure 2 Immunofluorescence identification of epithelial marker keratin antibody was performed on endometrial cells and oviduct mucosa cells of the second generation. The results showed that 8090% of the cytoplasm of endometrial cells and oviduct mucosa cells were stained with green fluorescence, showing positive cytokeratin antibodies. Microscopically, the cells were polygonal, spindle and spindle. Immunofluorescence identification of interstitial cell marker vimentin antibody was performed on endometrial cells and oviduct mucosa cells of the fifth generation. 80% of the cytoplasm of endometrial cells and oviduct mucosa cells were stained with red fluorescence under microscope. It showed positive cell vimentin antibody, and the cells were fusiform and polygonal under the microscope. (A1) The second generation of endometrial cells (DAPI). (A2) The second generation of endometrial cells (CK19). (A3) The second generation of endometrial cells (Merge). (B1) The second generation of oviduct mucosal cells (DAPI). (B2) The second generation of oviduct mucosal cells (CK19). (B3) The second generation of oviduct mucosal cells (Merge). (C1) The fifth generation of endometrial cells (DAPI). (C2) The fifth generation of endometrial cells (Vimentin). (C3) The fifth generation of endometrial cells (Merge). (D1) The fifth generation of oviduct mucosal cells (DAPI). (D2) The fifth generation of oviduct mucosal cells (Vimentin). (D3) The fifth generation of oviduct mucosal cells (Merge).
According to the same grouping method mentioned above, the growth curve was drawn after seven days of continuous measurement of endometrial cells and oviduct mucosa cells after co-culture. It can be seen that the growth rate of oviduct mucosa cells, when growing alone, was similar to that of endometrial cells in different proportions when co-cultured, without a significant statistical difference (P > 0.05). The growth curve was of the S type, which means they experienced three stages: slow growth stage, logarithmic growth stage, and plateau stage (Figure 3).
Figure 3 According to the same grouping method as mentioned above, the growth curve was drawn after 7 days of continuous measurement of endometrial cells and oviduct mucosa cells after co-culture. It can be seen that the growth rate of oviduct mucosa cells when growing alone was similar to that of endometrial cells in different proportions when co-culture, without significantly statistical difference (P > 0.05). The growth curve is of S type, which means that all of them experienced three stages: slow growth stage, logarithmic growth stage and plateau stage. TS: oviduct mucosal cells were cultured alone; T:E(1:1): the proportion of oviduct mucosal cells and endometrial cells was 1:1; T:E(1:0.5): the proportion of oviduct mucosal cells and endometrial cells was 1:0.5; T:E(1:0.1): the proportion of oviduct mucosal cells and endometrial cells was 1:0.1.
According to the same grouping method mentioned above, endometrial cells were co-cultured with oviduct mucosa epithelial cells and treated with decidualization. After 48 h of culture, oviduct mucosa cells induced by decidualization began to show decidual-like changes, with large and round cell volumes, rich and transparent cytoplasm, and blurred cell boundaries (Figure 4).
Figure 4 According to the same grouping method as mentioned above, endometrial cells were cocultured with oviduct mucosa cells and treated with decidualization. After 48 hours of culture, oviduct mucosa cells induced by decidualization began to show decidual-like changes, with large and round cell volumes, rich and transparent cytoplasm, and blurred cell boundaries. (A1) TS(40), (A2) TS(100), (A3) TS(200), (B1) T: E(1:1)(40), (B2) T:E(1:1)(100), (B3) T;E(1:1)(200), (C1) T:E(1:0.5)(40), (C2) T:E(1:0.5)(100), (C3) T:E(1:0.5)(200), (D1) T:E(1:0.1)(40), (D2) T:E(1:0.1)(100), (D3) T:E(1:0.1)(200).
The cells in each group were treated with decidualization by HE staining, and the cytoplasm was stained eosin, and the nucleus was blue. When oviduct mucosa cells were cultured alone and co-cultured with endometrial cells of different proportions, the cell morphology was unchanged, and all of them were fusiform, spindle, and polygonal, a round, large and centered cell nucleus (Figure 5).
Figure 5 The cells in each group were treated with decidualization by HE staining, and the cytoplasm was stained eosin and the nucleus was blue. When oviduct mucosa cells were cultured alone and co-cultured with endometrial cells of different proportions, the cell morphology was basically unchanged, and all of them were fusiform, spindle and polygonal, a round, large and centered cell nucleus. (A1) TS(100), (A2) TS(200), (B1) T:E(1:1)(100), (B2) T:E(1:1)(200), (C1) T:E(1:0.5)(100), (C2) T:E(1:0.5)(200), (D1) T:E(1:0.1)(100), (D2) T:E(1:0.1)(200).
Embryo implantation requires two crucial conditions. The first is the blastocyst formation, and the second is the endometrium, which has embryo receptivity. The implantation requires maturation of the endometrium with a certain thickness and endometrium epithelial cells and decidualization of stromal cells. The differentiation and maturation of the endometrium are known as the implantation window allowing embryo implantation. The synchronization of the two is vital. Studies have shown that embryo quality only accounts for one-third of implantation failure, and the other two-thirds are due to poor receptivity of the endometrium.9 Endometrium deletion and thin endometrium are important causes of poor endometrium receptivity, and therefore one of the key factors affecting the success of IVF-ET. Thin endometrium refers to the thickness of the endometrium that cannot reach the embryo implantation threshold. At present, it is generally believed that the minimum thickness of the endometrium during embryo implantation should be 7 mm, preferably greater than 9 mm, but not more than 14 mm. The endometrium thickness between 914 mm had the highest pregnancy rate.1012 However, there is no suitable method to solve the problem of thin endometrium and endometrium deficiency.
The etiology of IUA is due to the destruction of the endometrium basal layer due to various factors, lack of a source of endometrium regenerated cells, uterine wall fibrosis, uncontrolled deposition of extracellular matrix (ECM) and fibrous collagen, and replacement of the interstitial septum by fibrous tissue. The glands are replaced by inactive square columnar epithelium, so there is not enough endometrium to cover the uterine cavity, leading to intrauterine adhesions.
Due to the lack of endometrium regenerated cells in the uterus after extremely severe intrauterine adhesion separation surgery, endometrium could not grow even if given several drugs, resulting in a recurrence of IUA. Therefore, to prevent re-adhesion after IUA separation surgery, new cells need to be provided to the uterine cavity to grow and cover the uterine wall, and the new endometrium tissue should have the function of the endometrium. Mesenchymal stem cells (MSCs) are a kind of pluripotent stem cell, which have all the commonalities of stem cells, namely the ability of self-renewal and multidirectional differentiation. They are a research hotspot in regenerative medicine. Multiple sources of MSCs have been used for endometrium deficiency and thin endometrium studies, from animal models to human clinical trials, such as bone marrow, fat, menstrual blood, endometrium, umbilical cord, and oviduct. It has shown promising effects in promoting endometrium growth, improving endometrium basal layer regeneration capacity, inhibiting fibrosis, promoting angiogenesis, improving endometrium receptivity, and immune regulation, thus, improving patients reproductive outcomes.1319
However, it was found in a long-term follow-up that the clinical application of stem cells has caused many ethical and safety issues. For example, the local microenvironment of the transplanted site of MSCs cannot limit the differentiation of MSCs, and the uncertainty of its long-term differentiation may lead to unwanted differentiation in vivo, leading to serious consequences of exacerbation of the disease. In addition, MSCs may also promote tumor growth and metastasis by building a bridge between anti-tumor immune response and neovascularization in malignant tumors. Due to its immunomodulatory properties, it inhibits anti-tumor immune response, leading to increased tumor growth.2029 Its uncertain direction of differentiation, outcome, and malignant potential are significant safety issues, leading to doubts in the medical community regarding its therapeutic potential in the field of regenerative medicine.30 Therefore, better alternatives are needed.
Based on the similarity and homology between oviduct mucosa and endometrium mentioned above, we speculated that patients autologous oviduct mucosa could be transplanted into the uterine cavity to replace endometrium. In order to understand whether oviduct mucosa can grow in the uterine cavity and its growth situation, we used the culture fluid of endometrial cells cultured in vitro as the simulated endometrium microenvironment and put it into oviduct mucosa cells. In order to understand the coexistence of these two types of cells in the same environment, we observed the growth of oviduct mucosa cells in different concentrations of endometrial cells. A CCK8 cell proliferation experiment was conducted on oviduct mucosa cells grown in four groups of endometrial cell culture solutions with different concentrations. The growth curve indicated that oviduct mucosa cells could grow in a uterine environment with different endometrial proportions. The growth rate of oviduct mucosa was similar to that in the environment without endometrial cells, without excessive proliferation, suggesting that oviduct mucosa can grow in the endometrium microenvironment without being affected by the endometrium. The growth rate of endometrial cells in the co-culture environment was also consistent with that in the individual culture, suggesting that cell growth from the two sources did not inhibit each other.
In order to further understand the changes in the morphology and structure of oviduct cells in the uterine environment, we placed oviduct mucosa cells on the bottom of the co-culture dish and allowed them to grow in different concentrations of endometrial cells, and then took them out for HE staining. The cell morphology of the co-cultured oviduct mucosa cells was observed under a microscope when they grew in the culture solution of endometrial cells of different concentrations. The cell morphology was similar to that of the single culture, showing fusiform, polygonal, and fusiform, a round, large and centered cell nucleus. These results indicated that the cell morphology of oviduct mucosa cells was not affected when co-cultured with endometrial cells. In the co-culture system, endometrial cells and oviduct mucosa both grew at the same rate as when they were grown alone. Therefore, we speculated that in living tissues, oviduct mucosa might grow in the uterine cavity or be suitable for the growth of oviduct mucosa in the uterine cavity without affecting the growth of the original endometrium.
Decidualization is a progesterone-dependent differentiation process of endometrium mesenchymal cells, which refers to the transformation of endometrium mesenchymal fibroblasts into specialized secretory decidua cells, which provide an essential nutritional and immune environment for embryo implantation and placental development. It is a necessary condition for successful embryo implantation. In order to observe whether oviduct mucosa cells can undergo decidualization after co-culture and whether they have the conditions for embryo implantation, we also conducted in vitro decidualization induction after co-culture of two kinds of cells. It was found that after in vitro decidualization induction, the volume of oviduct mucosa cells became larger and rounded, the cytoplasm was rich and transparent, and the cell boundary became blurred and morphologically changed, which was the same as the cell morphology of endometrium decidualization.
In our study, we also observed that only part of the oviduct mucosa cells induced by in vitro decidualization after co-culture had morphologic changes of decidualization cells, but not all of them. This is also consistent with the study of oviduct mucosa taken from living tissues.31
Although salpingocyesis often has a bad outcome, it is currently believed that its causes include insufficient blood supply, excessively thin oviduct mucosa and muscle layer, insufficient decidualization reaction,32 and abnormal secretion of certain related factors. Therefore, if oviduct mucosa is put into the uterine cavity as a substitute for endometrium, it can at least solve the factors of its limited anatomical structure. However, insufficient oviduct mucosa decidualization may lead to abortion, placental implantation, and other outcomes. Enhancing its decidualization is a problem that needs to be solved both in the laboratory and clinic.
In conclusion, our results indicate that oviduct mucosa cells can grow normally in the environment with endometrium, and their morphology and growth speed are not affected. Morphological changes of oviduct mucosa cells can occur after in vitro decidualization treatment in the symbiosis of the two cells. There was no significant difference between the two cells in separate culture and co-culture in terms of HE staining. These findings lay a foundation for the possibility of oviduct mucosa instead of endometrium in the treatment of IUA. However, whether the growth of cells in vitro is consistent with that in vivo requires further animal experimental studies, and our current study has not yet involved the study of the specific functions of the two cells. Therefore, these questions need to be more important before it becomes the possibility of routine clinical practice. Many further experiments will be solved one by one, such as the comparative study of the related functions of the symbiotic fallopian tube mucosal cells and normal endometrial cells during embryo implantation, immune status, etc.
The study was conducted in accordance with the Declaration of Helsinki (as was revised in 2013). The study was approved by Ethics Committee of Affiliated Hospital of Guizhou Medical University [No. 2020-(264-01)]. Written informed consent was obtained from all participants.
We are particularly grateful to all the people who have given us help on our article.
This study was funded by the science and technology fund project of health Committee of Guizhou Province, China (No. gzwjkj2020-1-146).
The authors declare that they have no competing interests.
1. Senturk LM, Erel CT. Thin endometrium in assisted reproductive technology. Curr Opin Obstet Gynecol. 2008;20(3):221228. doi:10.1097/GCO.0b013e328302143c
2. Varga I, Miko M, Kachlk D, ikov M, Danihel Jr, Babl P. How many cell types form the epithelial lining of the human uterine tubes? Revision of the histological nomenclature of the human tubal epithelium. Ann Anat. 2019;224:7380.
3. Saint-Dizier M, Schoen J, Chen S, Banliat C, Mermillod P. Composing the early embryonic microenvironment: physiology and regulation of oviductal secretions. Int J Mol Sci. 2019;21(1):223.
4. Leese HJ. The formation and function of oviduct fluid. J Reprod Fertil. 1988;82(2):843856.
5. Makrigiannakis A, Karamouti M, Petsas G, Makris N, Nikas G, Antsaklis A. The expression of receptivity markers in the fallopian tube epithelium. Histochem Cell Biol. 2009;132(2):159167.
6. Qin L, Wang YL. Molecular basis of tubal pregnancy implantation window and expression of maternal-fetal interface related molecules. J Reprod Med. 2003;06:369373.
7. Slz L, Valenzuela JP, Salvatierra AM, Ortiz ME, Croxatto HB. The expression of alpha(v) and beta3 integrin subunits in the normal human Fallopian tube epithelium suggests the occurrence of a tubal implantation window. Hum Reprod. 1998;13(1O):29162920.
8. Goddijn M, van der Veen F, Schuring-Blom GH, Ankum WM, Leschot NJ. Cytogenetic characteristics of ectopic pregnancy. Hum Reprod. 1996;11(12):27692771.
9. Craciunas L, Gallos I, Chu J, et al. Conventional and modern markers of endometrial receptivity: a systematic review and meta-analysis. Hum Reprod Update. 2019;25(2):202223.
10. Momeni M, Rahbar MH, Kovanci E. A meta-analysis of the relationship between endometrial thickness and outcome of in vitro fertilization cycles. J Hum Reprod Sci. 2011;4(3):130137.
11. Sharma S, Rani G, Bose G, Saha I, Bathwal S, Chakravarty BN. Tamoxifen is Better than Low-Dose Clomiphene or Gonadotropins in Women with Thin Endometrium (<7 mm) after clomiphene in intrauterine insemination cycles: a prospective study. J Hum Reprod Sci. 2018;11(1):3439.
12. Zadehmodarres S, Salehpour S, Saharkhiz N, Nazari L. Treatment of thin endometrium with autologous platelet-rich plasma: a pilot study. JBRA Assist Reprod. 2017;21(1):5456.
13. Nagori CB, Panchal SY, Patel H. Endometrial regeneration using autologous adult stem cells followed by conception by in vitro fertilization in a patient of severe Ashermans syndrome. J Hum Reprod Sci. 2011;4(1):4348.
14. Gao L, Huang Z, Lin H, Tian Y, Li P, Lin S. Bone Marrow Mesenchymal Stem Cells (BMSCs) restore functional endometrium in the rat model for severe Asherman syndrome. Reprod Sci. 2019;26(3):436444.
15. Wang J, Ju B, Pan C, et al. Application of bone marrow-derived mesenchymal stem cells in the treatment of intrauterine adhesions in rats. Cell Physiol Biochem. 2016;39(4):15531560.
16. Santamaria X, Cabanillas S, Cervell I, et al. Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Ashermans syndrome and endometrial atrophy: a pilot cohort study. Hum Reprod. 2016;31(5):10871096.
17. Zhao G, Cao Y, Zhu X, et al. Transplantation of collagen scaffold with autologous bone marrow mononuclear cells promotes functional endometrium reconstruction via downregulating Np63 expression in Ashermans syndrome. Sci China Life Sci. 2017;60(4):404416.
18. Tan J, Li P, Wang Q, et al. Autologous menstrual blood-derived stromal cells transplantation for severe Ashermans syndrome. Hum Reprod. 2016;31(12):27232729.
19. Cao Y, Sun H, Zhu H, et al. Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a Phase I clinical trial. Stem Cell Res Ther. 2018;9(1):192.
20. Breitbach M, Bostani T, Roell W, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 2007;110(4):13621369.
21. Yoon YS, Park JS, Tkebuchava T, Luedeman C, Losordo DW. Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction. Circulation. 2004;109(25):31543157.
22. Kuriyan AE, Albini TA, Townsend JH, et al. Vision loss after intravitreal injection of autologous Stem cells for AMD. N Engl J Med. 2017;376(11):10471053.
23. Lazennec G, Jorgensen C. Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells. 2008;26(6):13871394.
24. Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, Rameshwar P. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol. 2010;184(10):58855894.
25. Wang X, Zhang Z, Yao C. Survivin is upregulated in myeloma cell lines cocultured with mesenchymal stem cells. Leuk Res. 2010;34(10):13251329.
26. Ljujic B, Milovanovic M, Volarevic V, et al. Human mesenchymal stem cells creating an immunosuppressive environment and promote breast cancer in mice. Sci Rep. 2013;3:2298.
27. Oswald J, Boxberger S, Jrgensen B, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 2004;22(3):377384.
28. Janeczek Portalska K, Leferink A, Groen N, et al. Endothelial differentiation of mesenchymal stromal cells. PLoS One. 2012;7(10):e46842.
29. Khakoo AY, Pati S, Anderson SA, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposis sarcoma. J Exp Med. 2006;203(5):12351247.
30. Volarevic V, Ljujic B, Stojkovic P, Lukic A, Arsenijevic N, Stojkovic M. Human stem cell research and regenerative medicinepresent and future. Br Med Bull. 2011;99:155168.
31. Randall S, Buckley CH, Fox H. Placentation in the fallopian tube. Int J Gynecol Pathol. 1987;6(2):132139.
32. Floridon C, Nielsen O, Holund B, et al. Localization and significance of urokinase plasminogen activator and its receptor in placental tissue from intrauterine, ectopic and molar pregnancies. Placenta. 1999;20(8):711721.
See more here:
A Simulation Study on the Growth of Oviduct Mucosa Cells in the Uterin | IJWH - Dove Medical Press
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
- NOT-AR-23-022: Request for Information on Themes for the NIAMS ... - National Institutes of Health (.gov) - December 3rd, 2023
- December 2023: Intramural Papers of the Month - Environmental Factor Newsletter - December 1st, 2023
- CNA Explains: What is cord blood banking and why do parents do it? - CNA - December 1st, 2023
- Regulation of myogenesis and adipogenesis by the electromagnetic ... - Nature.com - December 1st, 2023
- The effects of vitamin K on bone health - News-Medical.Net - December 1st, 2023
- Dr Hurwitz on Ongoing Investigations of the Use of CAR T-Cell ... - OncLive - December 1st, 2023
- Mitophagy in human health, ageing and disease - Nature.com - December 1st, 2023
- Adult Stem Cells - Stem Cells and the Future of Regenerative Medicine ... - November 29th, 2023
- Navigating The Regulatory Landscape Of Longevity Health Products ... - Mondaq News Alerts - November 29th, 2023
- MS breakthrough could lead to treatments that halt disease's ... - inews - November 29th, 2023
- Reprogramming tissue mechanically to promote wound healing - Phys.org - November 29th, 2023
- Latest Advances in Arthritis Diagnosis and Treatment at American ... - HealthDay - November 29th, 2023
- Sex-associated differences in frequencies and prognostic impact of ... - Nature.com - November 29th, 2023
- Hematologists Dive into the Current Treatment Landscape - OncLive - November 29th, 2023
- Team discovers protein crucial for B cell differentiation and antibodies - Phys.org - November 29th, 2023
- Science Talk - I survived cancer as a child and now I'm working to ... - The Institute of Cancer Research - November 29th, 2023
- First Edition: Nov. 29, 2023 - KFF Health News - November 29th, 2023
- Symptoms: Unilateral Hearing Loss and Tinnitus : The Hearing Journal - LWW Journals - November 29th, 2023
- Mitigation of sepsis-induced acute lung injury by BMSCs | IJN - Dove Medical Press - November 29th, 2023
- A Case of a Constricted Vessel: The Impact of Acute Myeloid ... - Cureus - November 29th, 2023
- Mum brushed off fatigue after having baby but fall sparked deadly diagnosis - The Mirror - November 29th, 2023
- How heritable is the epigenome? - Drug Discovery News - November 29th, 2023
- The Blueprint of Regeneration: Scientists Discover How to Turn Stem Cells Fate - Revyuh - November 27th, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - Marketscreener.com - November 27th, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - PharmiWeb.com - November 25th, 2023
- COVID-19 Pandemic's Adverse Effect on Bone Health in Young ... - HealthDay - November 25th, 2023
- Sickle cell breakthrough - The Indian Express - November 25th, 2023
- Wall thickness analysis method for judging the degree of lower ... - Nature.com - November 25th, 2023
- Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference - Yahoo Finance - November 23rd, 2023
- Disease Transmission and Diagnosis of Zika Virus - Cureus - November 23rd, 2023
- Gene-editing therapy for sickle cell earns conditional approval in UK - Sickle Cell Disease News - November 23rd, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - Newswire - November 21st, 2023
- Efficacy of ADSC-CM in Patients with Telogen Effluvium | SCCAA - Dove Medical Press - November 21st, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - PR Newswire - November 21st, 2023
- The Impact of CAR T Cell Therapy on Managing R/R LBCL - OncLive - November 21st, 2023
- Mansour bin Zayed witnesses inauguration of ADSCC Bone Marrow Transplant & Cellular Therapy Congress 2023 - ZAWYA - November 21st, 2023
- Listeria: Who is most susceptible? What are the Symptoms? What ... - Food Poison Journal - November 21st, 2023
- Scope Of Issued Patents May Be Limited By Prosecution Estoppel ... - Mondaq News Alerts - November 21st, 2023
- Qrons Announces the Addition of Professor Shiri Navon-Venezia to ... - StreetInsider.com - November 21st, 2023
- Financially strapped Athersys raises $10.4M - cleveland.com - November 19th, 2023
- From the India Today archives (2010) | How stem cells can save your life - India Today - November 19th, 2023
- Inactivation of the tumor suppressor gene Apc synergizes with H ... - Science - November 19th, 2023
- The Origins of Multiple Myeloma and Why it Matters - HealthTree For AML - Acute Myeloid Leukemia - November 19th, 2023
- Treatment Considerations With TROP2-Targeted Therapy - OncLive - November 19th, 2023
- Athersys narrows loss, raises $10.4 million during third quarter to ... - The Business Journals - November 17th, 2023
- Who was Dolly the Sheep and what happened to her? The story of ... - BBC Countryfile Magazine - November 17th, 2023
- UK first to approve CRISPR treatment for diseases: what you need to ... - Nature.com - November 17th, 2023
- 1st sickle cell patient to be given therapy restoring fetal hemoglobin - Sickle Cell Disease News - November 15th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates - Century - Benzinga - November 13th, 2023
- Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer - Yahoo Finance - November 11th, 2023
- Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in... - November 11th, 2023
- AAO 2023: Paul Runge and his ROP treatments in the Ukraine - Modern Retina - November 11th, 2023
- The Evolutionary Reasons We Are Drawn To Horror Movies and ... - Slashdot - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - GlobeNewswire - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 9th, 2023
- NYU Langone Health Performs World's First Whole-Eye & Partial ... - NYU Langone Health - November 9th, 2023
- BrainStorm to Announce Third Quarter 2023 Financial Results and ... - BioSpace - November 9th, 2023
- Can we cut cost and pain of IVF? Start-up CEO tries out own ... - Genetic Literacy Project - November 9th, 2023
- Jasper Therapeutics Reports Third Quarter 2023 Financial Results ... - BioSpace - November 9th, 2023
- Impaired neural stress resistance and loss of REST in bipolar ... - Nature.com - November 9th, 2023
- Functional genomics and systems biology in human neuroscience - Nature.com - November 9th, 2023
- Trial launched to test CAR T-cell therapy in dogs diagnosed with ... - EurekAlert - November 9th, 2023
- The-Gut's-Lasting-Impact-on-Severe-COVID-19-Immune-Response - Infectious Disease Special Edition - November 9th, 2023
- Emerging Cure for Sickle Cell on its Way to FDA Approval, Carries ... - Dallasweekly - November 7th, 2023
- The science works, but will we pay for it? - Irish Medical Times - November 7th, 2023
Recent Comments